Kestra Private Wealth Services LLC Acquires 220 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Kestra Private Wealth Services LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.9% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,926 shares of the biopharmaceutical company’s stock after buying an additional 220 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Regeneron Pharmaceuticals were worth $1,372,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Mizuho Securities USA LLC grew its position in shares of Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after acquiring an additional 51,162 shares during the period. Principal Financial Group Inc. lifted its stake in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Simplify Asset Management Inc. grew its holdings in Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after purchasing an additional 3,231 shares during the period. Golden State Equity Partners increased its position in Regeneron Pharmaceuticals by 1,479.1% in the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after buying an additional 1,272 shares during the last quarter. Finally, Catalytic Wealth RIA LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $1,334,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.2 %

NASDAQ REGN opened at $663.86 on Thursday. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $72.95 billion, a P/E ratio of 17.34, a P/E/G ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The firm has a 50-day moving average price of $712.69 and a 200 day moving average price of $903.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the business posted $11.86 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.53%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on REGN. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research note on Tuesday, February 4th. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. JPMorgan Chase & Co. cut their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Finally, Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.